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Results of  a series  of  studies  on the cause of  the hypercalcemia that occurs  in mice 
bearing the HSDM~ fibrosarcoma (1-6)  and in rabbits  carrying  the VX2 carcinoma (7-9) 
have led us to conclude that these  two tumors synthesize  and secrete  large amounts of 
prostaglandin E2 (PGE2) into  plasma.  ~ PGE~ is a potent bone resorption-stimulating 
agent in vitro  (2, 10),  and this  prostaglandin and its metabolites are found in elevated 
concentrations  in the plasma of  tumor-bearing  animals (2, 3, 6-8, 11).  Because of  the 
rapid clearance and metabolism of  PGE2, measurements in plasma of  the metabolite, 
13,14-dihydro-15-keto-PGE2(PGE2-M), give a more accurate estimate of  PGE~ secretion 
than do measurements of  the primary prostaglandin itself  (6, 8, 11, 12).  Studies on the 
time-course of  the development of  elevated plasma calcium concentrations  and hyper- 
prostaglandinemia,  as well as investigations using two inhibiters of prostaglandin 
synthesis, indomethacin (1-3,  7) and hydrocortisone (6, 8, 13),  support the hypothesis 
that  the hypercalcemic syndrome in  these  tumor-bearing animals is  due to  the secretion 
of  PGE2 by the tumor. A similar  pathophysiologic  mechanism may explain  in part  the 
hypercalcemia that occurs  in certain  patients  with cancer (14-16). 
The present investigation was initiated because of  the observation that the 
plasma from rabbits bearing the VX~ carcinoma became faintly  blue about I wk 
after tumor  implantation,  and  this color increased  markedly  and  became 
intense by 3-4 wk. The time-course of  the appearance and increase in the blue 
color in plasma was similar to  that which we had previously noted for PGEz-M. 
We therefore undertook to identify the blue material in plasma and to examine 
the relationship  of its increase to prostaglandin  metabolism.  Our  findings 
indicate that the material is ceruloplasmin, that its rise  correlates closely with 
plasma concentrations of PGE2-M,  and that beth PGE2-M  and ceruloplasmin 
increase in the plasma  of tumor-bearing  rabbits before the development  of 
hypercalcemia. 
* Supported in part by research grants AM 10206, CA 17309, CA 19416, and AI 14157 from the 
National Institutes of Health. 
Professor of Biochemistry of the American Cancer Society (Award PRP-21). 
1Abbreviations  used  in  this  paper:  dl,  deciliter;  PGE2,  prostaglandin  E~;  FGE~-M,  13,14- 
dihydro- 15-keto-PGE2. 
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Ceruloplasmin is  a  blue,  copper-containing a2-globulin which possesses  in- 
trinsic oxidase activity (17-19). Its concentration in plasma is known to vary in 
a variety of physiologic states and in disease (18).  Decreased plasma levels have 
been  detected  in  Wilson's  disease,  nephrosis,  and  malabsorption  syndromes, 
and elevated concentrations are seen in acute and chronic infections, rheuma- 
toid arthritis, pregnancy, during estrogen administration, and in patients with 
a  variety  of  different  tumors.  The  mediators  which  control  ceruloplasmin 
synthesis and secretion by the liver in health and disease have not been clearly 
defined. 
Plasma concentrations of haptoglobin,  another ~2-globulin which binds  he- 
moglobin, are known to vary in parallel with ceruloplasmin in certain states of 
disease,  notably  acute  and  chronic  infection,  and  in  patients  with  certain 
malignancies  (20).  Furthermore,  it  has  been  reported  that  administration  of 
PGE1 can elevate the concentration of haptoglobin in the serum of rabbits (21). 
We therefore measured haptoglobin as well as ceruloplasmin in the plasma of 
rabbits bearing the VX2 carcinoma, and we found elevations which paralleled 
those  of the  copper-containing protein.  A  preliminary  presentation  of these 
findings has been made (22). 
Materials  and  Methods 
Animals.  The  VX2  carcinoma  was  passed  serially  in  female  albino  rabbits  by  methods 
previously described in detail (7). In experiments in which rabbits were treated with indomethacin 
from the time of  tumor implantation,  the drug was administered orally in an average daily dosage 
of 10-40 rag/rabbit/24 h.  Indomethacin  was incorporated  into  a  known amount of pulverized 
Purina Lab Chow for Rabbits (Ralston Purina Co., St. Louis, Mo.) which the animals consumed 
essentially  completely each  24  h  (7). In  experiments  in  which  rabbits  were  treated  with 
indomethacin intermittently  after the development of hypercalcemia, the drug was suspended in 
15% gelatin  and administered  by subcutaneous injection twice a day in a daily dosage of 10-20 
rag/rabbit.  The animals  weighed 2.5-3.0 kg.  For periods up to 4 wk after  tumor implantation, 
these rabbits did not become azotemic as determined by measurements  of plasma urea nitrogen 
and creatinine.  The exact schedules by which indomethacin was given are indicated in Results. 
Blood Collection.  Blood  was collected from a marginal ear vein or by cardiac puncture  into 
heparinized tubes or syringes. Plasma was separated  immediately by centrifugation  at 4°C. 
Ceruloplasmin.  The  concentrations  of ceruloplasmin  in  plasma  were  estimated  by  two 
independent methods. The first method used the procedure of Sunderman and Nomoto (23) which 
depends on the p-phenylenediamine  oxidase activity of ceruloplasmin. The standard was human 
ceruloplasmin,  type III, from Sigma Chemical Co., St. Louis, Mo. (lot 114C-0237-1). The second 
method  used  Laurell's  electroimmunoassay  technique  (24, 25). The  antiserum  was  prepared 
against  purified  human  serum  ceruloplasmin  in  goats,  and  it  was  obtained  from  Atlantic 
Antibodies, Westbrook, Maine. This antiserum  cross-reacted sufficiently with rabbit ceruloplas- 
min to provide easily identified rockets. The immunoassay results were expressed as a percentage 
of the basal ceruloplasmin concentration before tumor implantation  for each animal. 
Immunochemical Measurements of Plasma Haptoglobin and Albumin.  The concentrations of 
haptoglobin and albumin in plasma were measured by electroimmunoassay (24, 25) using antisera 
prepared  against  analogous purified human serum  proteins  in goats (Atlantic  Antibodies). As 
with  ceruloplasmin,  these  antisera  cross-reacted  sufficiently  with  the  corresponding  rabbit 
plasma  proteins to give clear rockets. The results  were expressed as a percentage  of the basal 
concentration of that protein before tumor implantation  for each animal. 
Prostaglandin  Metabolite.  The  metabelite  of PGE2, PGE2-M, was measured  in plasma  by 
radioimmunoassay  (26). The anti-PGE2-M cross-reacted with 13,14-dihydro-PGE2, 15-keto-PGEz, 
13,14-dihydro-15-keto-PGF2~, 13,14-dihydro-15-keto-PGA2,  PGE2, and PGA2 0.2, 7.0, 5.0, 0.4, 0.1, 
and 0.08%, respectively  (26). Plasma  for PGE2-M assay was extracted  with  3 vol of methylal- 
ethanol  and concentrated  as described previously for human samples  (27). Several extracts  of 1(}80  PLASMA  CERULOPLASMIN,  HAPTOGLOBIN,  AND  PROSTAGLANDINS 
rabbit  plasma  were  assayed  with  anti-13,14-dihydro-15-keto-PGF2~.  The  13,14-dihydro-15-keto- 
PGE2  gave a  cross-reaction  with  this  anti-PGF2~  metabolite of ----3% (28). These  simultaneous 
radioimmunoassays  demonstrated  that  it was the PGE~  metabolite,  not the PGF2~ metabolite, 
that  was  being  measured  in  the  experiments  in  this  report.  Similar quantitative  results  for 
plasma PGE~-M have been measured in rabbits basally and during the first 3 wk after VX2 tumor 
implantation  using  high  performance  liquid  chromatography  and  gas  chromatography-mass 
spectrometry  (11).  The  sensitivity of the radioimmunoassay  method  was  15  pg of PGE~-M/ml 
rabbit plasma, and the precision of a  measured value was -+20%. 
Calcium.  The concentration of calcium in plasma was measured  in duplicate  by automatic 
fluorometric titration  with  a  Corning model 940  calcium  analyzer  (Coming Medical,  Coming 
Glass Works, Medfield, Mass.). 
Statistical Method.  Where appropriate, when groups of rabbits were studied, the results were 
subjected to an analysis of variance,  and the standard  errors were calculated from the residual 
error term of that analysis. 
Results 
Plasma Ceruloplasmin.  The concentration of ceruloplasmin in the plasma 
of 12  normal control rabbits  was  37  _+  4  mg/deciliter  (dl)  (mean  _  SE),  as 
measured by its p-phenylenediamine oxidase activity. This value is similar to 
that found in normal human serum,  31.5  _+  5 mg/dl (mean  _+  SD),  using the 
same technique (23). 
The rise in plasma ceruloplasmin as a function of time after implantation of 
VX2 tumor cells in three rabbits is shown in Fig. 1. A marked increase of 10 to 
20  times the basal concentration was seen 3-4  wk after tumor implantation. 
There was generally good agreement between the results obtained on the same 
samples by both the chemical and immunological assay methods (Fig. 1). The 
largest discrepancy observed in over 25 rabbits studied was that seen in rabbit 
224 (Fig. 1 C) between 1.5 and 2.5 wk. 
Plasma Haptoglobin and Albumin.  Fig. 2 A shows that plasma haptoglobin 
rose markedly after tumor implantation in three rabbits. In the same animals, 
there was little or no change in the concentration of albumin in plasma (Fig. 
2 B).  Similar results were observed in five other rabbits. 
Relationship of Plasma Ceruloplasmin to Plasma Prostaglandin Metabolites 
and Calcium.  We have reported previously that PGE2-M  rises rapidly in the 
plasma of rabbits bearing the VX2 carcinoma (8). The rise in PGE2-M  is much 
greater than the increase in PGE2 itself (8, 11) and it precedes the elevation of 
plasma calcium concentration. The time-courses of changes in the concentra- 
tions of PGE2-M,  ceruloplasmin, and calcium in plasma in three rabbits bearing 
VX2  carcinomas  are  shown  in  Fig.  3.  In  each  rabbit,  plasma  PGE2-M  and 
ceruloplasmin  rose  earlier  after  tumor  cell  implantation  than  did  plasma 
calcium. Plasma PGE2-M and ceruloplasmin rose between wk 1 and 2, whereas 
plasma calcium did not rise above basal concentrations until 2-3 wk after tumor 
implantation (Fig. 3). These relationships are more clearly displayed when the 
results obtained in a group of rabbits are pooled and plotted together (Fig. 4). It 
is seen that the rises in plasma PGE2-M  and ceruloplasmin occur at approxi- 
mately the same time, and that both precede the increase in plasma calcium. 
At 1 wk, plasma PGE2-M was 340  +_  100 pg/ml (mean _+ SE) as compared to a 
control value of 100 _  30 pg/ml (P <  0.05), and plasma ceruloplasmin was 55 _+ 
5 mg/dl as compared to a control value of 37  -  4 mg/dl (P  <  0.05). 
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FIG. 1.  Time-course of  rise  of  plasma ceruloplasmin in  three rabbits:  (A),  Ra 177;  (B),  Ra 
135; and (C),  Ra 224 after implantation  of VX2 tumor cells  at 0 wk. The same plasma 
samples were assayed by the chemical  (-~  0) and immunological  (O---O)  assay 
procedures described in Materials and Methods. The samples for  immunoassay were ceded 
and ceruloplasmin  was measured without knowledge of the experimental protocol.  The 
data are plotted  as fold  increase (incr.)  above the control  basal value (set  at 1.0)  for  each 
rabbit measured before tumor implantation. 
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FIG.  2.  Time-course of  change in  plasma haptoglobin (A)  and plasma albumin (B)  in  three 
rabbits:  Ra 135 (e),  Ra 224 (I),  and Ra 177 (O) after  implantation of  VX~ tumor cells  at 0 
wk. The data are plotted  as fold  stimulation above the control  basal value (set  at 1.0)  for 
each rabbit measured before tumor implantation. 1082 
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calcium (@  S) in three rabbits (Ra 209, Ra 234, and Ra 237) after implantation of VX2 
tumor cells at 0 wk. The data for PGE2-M and calcium are given as absolute concentrations 
in plasma, while those for ceruloplasmin (CP) are plotted as fold increase above the control 
basal value (set at 1.0)  for each rabbit measured before tumor implantation. 
anti-inflammatory  drug  indomethacin  is  a  potent  inhibitor  of prostaglandin 
synthesis (29), and when administered to rabbits bearing the VX2 carcinoma, it 
prevents the rise in plasma calcium (7), plasma PGE2 (7), and plasma PGE2-M 
(8), as well as decreasing the PGE2 content of the tumor (7). Indomethacin also 
inhibits the synthesis of PGE2 by strains of VX2 tumor cells in culture (7). 
In two rabbits, indomethacin administration  was begun at the time of tumor 
cell implantation,  and plasma calcium, ceruloplasmin, and haptoglobin concen- 
trations  were measured  (Fig.  5).  In contrast to the expected large rises in all 
three plasma components (Figs. 1-4), there was no increase in plasma calcium, 
and  little  or no change  in plasma  ceruloplasmin  and  haptoglobin  (Fig.  5).  If 
tumor-bearing  rabbits  were  permitted  to  develop elevated  concentrations  of 
PGE2-M and ceruloplasmin in plasma and were then treated with indometha- 
cin,  the  continued  rise  in  both  plasma  components  was  inhibited,  or  both 
components  fell  in  parallel  (Fig.  6).  In  Fig.  6A,  temporary  cessation  of 
indomethacin  administration  was followed by an  increase in plasma PGE2-M 
and  ceruloplasmin,  both  of  which  were  decreased  by  a  second  course  of 
treatment with indomethacin. 
Discussion 
From  the  results  presented  in  this  communication  we  conclude  that  the 
concentrations of the acute phase reactants, ceruloplasmin and haptoglobin, are 
elevated in the plasma of rabbits bearing the VX2 carcinoma.  The validity of 
this  conclusion  depends  on  the  specificity of the  findings  and  of the  assay 
methods  used.  The  clue that  initiated  our studies  was the  blue color of the 
plasma of tumor-bearing rabbits.  Ceruloplasmin is a  blue protein  (17-19). The 
color of the rabbit plasma was not characteristic  of bilirubin,  the rabbits had 
neither  hepatic metastases  nor bile duct occlusion,  and plasma bilirubin was 
not elevated (unpublished data). All plasma proteins were not elevated nonspe- 
cifically because plasma albumin remained unchanged (Fig. 2). Ceruloplasmin 
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Fro. 4.  Time-courses of  changes in plasma PGE2-M, calcium, and ceruloplasmin  (CP) in 
a group of  rabbits  after  implantation of  VX2 tumor cells  at  0 wk. Each point  gives  the  mean 
value of  7-12 rabbits  and the bars give the SE. Rises above control  values for  PGE2-M and 
ceruloplasmin were statistically  significant  (P < 0.05)  at i  wk and highly significant  (P < 
0.001)  at 1.5  wk, whereas the  rise  in  plasma calcium did not  become statistically  significant 
until 3 wk. 
utilizing  the p-phenylenediamine oxidase activity of ceruloplasmin,  and  an 
immunological assay,  and  the  results  of the  two  techniques were  in  good 
agreement. Furthermore, the subjective assessment of the increase in intensity 
of blue color in plasma correlated well with the results of both quantitative 
assay methods. 
The time-courses of the rises in plasma ceruloplasmin and PGE2-M in rabbits 
bearing the VX2 carcinoma were very similar,  and both clearly preceded the 
increase in plasma calcium (Fig.  4).  We suggest the following hy.pothesis  to 
explain our findings. The VX2 tumor synthesizes and secretes large amounts of 15 
PL  A SMA 
CALCIUM 
(mg/dl)  t3 
It 
2  3 
PLASMA  4 
CERULOPL  ASMIN 
( fold increose ) 
PLASMA 
HA  P TOGL  OBIN 
(fold increose ) 
Indomethocin 
_  I  I 
-~  Rot56 
Re 124 
I  I  I  I  I 
2 
t 
I  I  I  I  I 
0  !  2  3  4 
WEEKS 
Fro. 5.  Two rabbits,  Ra 124 (e) and Ra 156 (O),  were implanted  with VX2 tumor cells  at 
0 wk, and indomethacin (40 rag/rabbit/day,  orally)  therapy was begun immediately. 
Plasma calcium, ceruloplasmin, and haptoglobin were measured at intervals  as described 
in Materials and Methods and plotted  as described  in the legends to  previous figures. 
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FIG. 6.  Time-courses of rises of plasma  PGE~M  (A  A)  and ceruloplasmin  (CP) 
(O-  -  -O) in  three rabbits:  (A),  Ra 255;  (B),  Ra 260;  and (C),  Ra 261,  after  implantation of 
VX2 tumor  cells  at  0  wk. The rabbits  were  treated  intermittently  with  indomethacin (10-20 
mg/rabbit/day).  Indomethacin  administration  is  indicated  at  the  top  of  each  panel  by  I  over 
the shaded area.  The data for  plasma ceruloplasmin are plotted  as fold  increase  above  the 
control  basal value (set  at 1.0)  for  each rabbit  measured before  tumor implantation. 
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PGE2  (7,  8,  11).  Of the products of arachidonic  acid metabolism secreted into 
plasma, PGE2 is best measured as the accumulated metabolite, PGE2-M because 
of the rapid clearance and metabolism of PGE~ itself (8, 11, 12). One or more of 
these arachidonic acid metabolites, possibly PGE2 or PGE2-M, acts on the liver 
to stimulate the synthesis and secretion ofceruloplasmin (and also haptoglobin). 
This  effect is  more  rapid  and/or  more  sensitive  to  circulating  arachidonate 
metabolites than  is the  action of PGE~ on bone; thus the increase  in plasma 
ceruloplasmin occurs before the hypercalcemia.  We acknowledge that we have 
at  this  time  no  experimental  evidence  that  the  effect of the  arachidonate 
metabolite  is a  direct action on the liver;  it could be occurring  indirectly  via 
some additional mediator.  Nevertheless, such a  metabolite would appear to be 
a relevant intermediate in the pathway between tumor and hyperceruloplasmi- 
nemia because its synthesis was inhibited by indomethacin, and there was little 
or no rise in plasma ceruloplasmin (or haptoglobin) in the presence of indometh- 
acin.  The  validity of this  interpretation  depends on the  assumption  that  the 
doses of indomethacin  used did not have effects on ceruloplasmin  (or haptoglo- 
bin) synthesis, release, or metabolism that are independent of the actions of the 
drug on prostaglandin synthesis. To our knowledge, no such effects of indometh- 
acin  have  been  reported,  and  no changes  in  plasma  albumin  concentrations 
were noted by us in rabbits treated with indomethacin. 
The biological significance of our findings  is of possible general  interest.  A 
body of evidence  has  accumulated  that  supports  the  view that  a  number  of 
aspects of the inflammatory response are mediated via arachidonic acid metab- 
olites and that the anti-inflammatory  actions of aspirin-like  drugs are due to 
their inhibitory effects on the fatty acid cyclooxygenase (30-32). In this context, 
the frequent association of elevated plasma concentrations of ceruloplasmin and 
haptoglobin with acute and chronic inflammatory processes is noteworthy. We 
have  no  evidence  to  suggest  that  in  generalized  inflammatory  diseases the 
plasma  concentrations  of PGE2,  PGE2  metabolites,  or  other  metabolites  of 
arachidonic  acid  are  elevated,  although  the  tissue  levels  may  be  high  at 
localized  sites  of  inflammation.  On  the  other  hand,  inflammatory  stimuli 
appear  to  enhance  the  synthesis  and  release  of PGE2,  and  possibly  other 
metabolites of arachidonic acid, from macrophages (33). Thus it is possible that 
certain  inflammatory  stimuli  lead  to  elevations  in  plasma  of acute  phase 
reactants,  including  ceruloplasmin  and  haptoglobin,  via  a  pathway  which 
depends on arachidonic acid metabolism. Consistent with this hypothesis is the 
observation that systemically administered PGE1 causes a marked rise in serum 
haptoglobin in the rabbit (21). 
In the case of tumors associated with elevations of plasma ceruloplasmin and 
haptoglobin,  our findings indicate that,  at least in the specific instance of the 
VX2 carcinoma,  the rise in these two acute phase reactants occurs in animals 
bearing a PGE2-producing tumor. The large magnitude (10- to 20-fold) and early 
rise  in plasma ceruloplasmin  in rabbits carrying the  VX2 carcinoma  indicate 
that  this  easily  measured  plasma  protein  may  be  used  to  monitor  tumor 
presence and possibly the effects of anti-tumor therapy.  Whether or not these 
observations  could be extended  to  certain  human  tumors  remains  uncertain 
because of the probable multiplicity of factors controlling acute phase reactants 
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Summary 
Results of previous studies have  shown that  the  VX2 carcinoma  in rabbits 
synthesizes  large  amounts  of prostaglandin  E2  (PGE2).  PGE2  secreted by the 
tumor is rapidly metabolized and can be measured in plasma as the metabolite 
13,14-dihydro-15-keto-PGE2  (PGE2-M).  We have  previously proposed that  the 
hypercalcemia  that  occurs  in  rabbits  bearing  the  VX2  carcinoma  is  due  to 
excessive secretion  of PGE2  by the  tumor  and  its  subsequent  action  on  the 
skeleton as a bone resorption-stimulating  factor. In the course of these studies, 
we noted that  the plasma of rabbits bearing the VX2 carcinoma  became blue 
about  1  wk  after  tumor  implantation.  The  intensity  of the  color  increased 
markedly thereafter.  We therefore measured ceruloplasmin in plasma by both 
chemical and immunological assay methods.  Plasma ceruloplasmin and PGE2- 
M rose in parallel (within 7-10 days) and preceded by 7-10 days the development 
of hypercalcemia.  2 wk after tumor implantation,  plasma PGE2-M and cerulo- 
plasmin had risen about 20- and 6-fold, respectively, while the rise in plasma 
calcium  was  just  beginning.  Indomethacin,  an  inhibitor  of  prostaglandin 
synthesis, given from the time of tumor implantation prevented completely the 
hypercalcemia  and  largely  inhibited  the  rise  in  ceruloplasmin.  When  given 
after hyperprostaglandinemia  had developed, indomethacin  produced a  fall in 
both PGE2-M and ceruloplasmin.  A  rise in plasma haptoglobin concentrations 
similar to that seen for ceruloplasmin was also observed. No changes in plasma 
albumin concentrations occurred.  We conclude that the acute phase reactants 
ceruloplasmin and haptoglobin rise rapidly in the plasma of rabbits bearing the 
VX2 carcinoma, and that this increase is related to arachidonic acid metabolism 
in these animals. It is possible that arachidonic acid metabolites also play a role 
in the elevations of these two plasma proteins observed in certain patients with 
malignant  tumors. 
We thank Yolanda Santo and Diane Balavitch Banda for their expert assistance, and Elizabeth 
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